| Northside Medical Clinic, P.c. | |
|
31 Hughes Dr Jackson TN 38305-1505 | |
| (731) 668-2800 | |
| (731) 668-6161 |
| Full Name | Northside Medical Clinic, P.c. |
|---|---|
| Speciality | Family Medicine |
| Location | 31 Hughes Dr, Jackson, Tennessee |
| Authorized Official Name and Position | John R. Blenis (ADMINISTRATOR) |
| Authorized Official Contact | 7316682800 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Northside Medical Clinic, P.c. 31 Hughes Dr Jackson TN 38305-1505 Ph: (731) 668-2800 | Northside Medical Clinic, P.c. 31 Hughes Dr Jackson TN 38305-1505 Ph: (731) 668-2800 |
| NPI Number | 1083781595 |
|---|---|
| Provider Enumeration Date | 11/29/2006 |
| Last Update Date | 12/04/2012 |
| Medicare PECOS PAC ID | 1759283765 |
|---|---|
| Medicare Enrollment ID | O20040121000831 |
News Archive
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
A coronavirus test made by Abbott Laboratories and introduced with considerable fanfare by President Donald Trump in a Rose Garden news conference this week is giving state and local health officials very little added capacity to perform speedy tests needed to control the COVID-19 pandemic.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083781595 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Marion J Scott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952494643 PECOS PAC ID: 5991731556 Enrollment ID: I20050714000598 |
News Archive
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
A coronavirus test made by Abbott Laboratories and introduced with considerable fanfare by President Donald Trump in a Rose Garden news conference this week is giving state and local health officials very little added capacity to perform speedy tests needed to control the COVID-19 pandemic.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
› Verified 6 days ago
| Provider Name | Timothy W Hayden |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972699494 PECOS PAC ID: 1951337559 Enrollment ID: I20050714000879 |
News Archive
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
A coronavirus test made by Abbott Laboratories and introduced with considerable fanfare by President Donald Trump in a Rose Garden news conference this week is giving state and local health officials very little added capacity to perform speedy tests needed to control the COVID-19 pandemic.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
› Verified 6 days ago
| Provider Name | Elizabeth S Londino |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922194778 PECOS PAC ID: 6204862808 Enrollment ID: I20050714000889 |
News Archive
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
A coronavirus test made by Abbott Laboratories and introduced with considerable fanfare by President Donald Trump in a Rose Garden news conference this week is giving state and local health officials very little added capacity to perform speedy tests needed to control the COVID-19 pandemic.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
› Verified 6 days ago
| Provider Name | Hannah M Keymon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952045197 PECOS PAC ID: 6305228438 Enrollment ID: I20220805000161 |
News Archive
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
A coronavirus test made by Abbott Laboratories and introduced with considerable fanfare by President Donald Trump in a Rose Garden news conference this week is giving state and local health officials very little added capacity to perform speedy tests needed to control the COVID-19 pandemic.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
› Verified 6 days ago
News Archive
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
A coronavirus test made by Abbott Laboratories and introduced with considerable fanfare by President Donald Trump in a Rose Garden news conference this week is giving state and local health officials very little added capacity to perform speedy tests needed to control the COVID-19 pandemic.
The U.S. Food and Drug Administration has awarded a contract to Harvard Pilgrim Health Care Inc. to develop a pilot of the FDA's Sentinel System, which will use automated health care data to evaluate medical product safety.
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
› Verified 6 days ago
Therapy & Learning Center Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 32 Garland Dr, Jackson, TN 38305 Phone: 731-668-3322 Fax: 731-664-2491 | |
Wellness Clinic And Family Care Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 21 Meridian Springs Dr, Jackson, TN 38301 Phone: 731-256-0526 Fax: 731-256-1720 | |
Ultimate Health Clinic North Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 16 Murray Guard Dr Ste B, Jackson, TN 38305 Phone: 731-660-0887 Fax: 731-660-9996 | |
West Tennessee Medical Group Ut Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 294 Summar Dr, Jackson, TN 38301 Phone: 731-423-1932 Fax: 731-660-8739 | |
The Medical Clinic Of Jackson Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 587 Skyline Dr, Jackson, TN 38301 Phone: 731-424-8922 Fax: 731-423-2922 | |
West Tennessee Medical Group Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 620 Skyline Dr, Jackson, TN 38301 Phone: 731-660-8730 Fax: 731-660-8739 |